Personalized Cancer Treatment Programs

Objective

To explore patient experiences and outcomes in personalized oncology treatment programs

Approach

  • Qualitative: In-depth interviews with patients undergoing personalized cancer treatment.
  • Quantitative: Analysis of treatment outcomes and survival rates.

Markets covered


USA


India


UK


Japan


Germany

Sample Size

  • Qualitative: 25 patients' interviews.
  • Quantitative: 300 patients' interviews.

Findings

Personalized treatment programs led to better patient outcomes, including higher survival rates and improved quality of life. Patients reported a high level of satisfaction with the tailored approach, highlighting the importance of personalized care in oncology.

Our Global Clients

Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.

SPER-Astellas Pharma
SPER-Microsoft
SPER-EY
SPER-McKinsey
SPER-Bain
SPER-Max-Healthcare
SPER-DHL
SPER-IQVIA
SPER-Mitsubishi Logistics
SPER-PACCOR
SPER-Macmillan Education
SPER-Kankar IMRB
SPER-ITA
SPER-PWC
SPER-SAPTCA
SPER-Straumann
SPER-MENARINI Silicon Biosystems
SPER-IPSOS
SPER-Heineken